In a pooled analysis of glycemic control trials with oral semaglutide, diabetic retinopathy complications occurred in 4.2% of T2DM patients receiving semaglutide and 3.8% with comparator
CrossRef Anti-diabetic Drugs and Cancer: Integrated Mechanisms of Tumor Suppression and Clinical Translation Mahya Asadalizadeh, Mohammad Kazem Molavi Rahbar, Tabassom Mahmoudie, Mahshid Abbasi, Mitra Akbari, Davoud Shakiba, Aida Mohammadiun Shabestari, Meysam Ebrahimifar Indian Journal of Clinical Biochemistry.2026;[Epub] CrossRef Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis Gaetano Lauri, Paolo Giorgio Arcidiacono, Antonio Facciorusso, Gabriele Capurso, Matteo Tacelli Pancreatology.2026;[Epub] CrossRef GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns Klaudia Nowak, Krzysztof upina, Aleksandra Kalisz, ucja Ilkiewicz, Jakub Janczura Current Pharmacology Reports.2026;[Epub] CrossRef Optimizing glycemic control in oncology patients with diabetes mellitus S
Thats why fad diets or extreme restriction often backfire
Puder: What I think is the most wild thing about this is the average human, without any glucose regulation issues, they probably have on average about one teaspoon of total sugar, total glucose in their blood at a given time
